Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 55-61

  Guo, Weijie ^a,b   Zhao, Yingjun ^b   Zhang, Zhenfeng ^b   Tan, Ning ^b   Zhao, Fangyu ^b,c   Ge, Chao ^b   Liang, Linhui ^b   Jia, Deshui ^a,b   Chen, Taoyang ^d   Yao, Ming ^b,c   Li, Jinjun ^b   He, Xianghuo ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Qi Dong Liver Cancer Institute   (China)

Author keywords

Autophagy; Hepatocellular carcinoma; ROS; Tumorigenecity; XCT

Indexed keywords

AMINO ACID TRANSPORTER; GLUTATHIONE; PROTEIN XCT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SULFASALAZINE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053304909     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.024     Document Type: Article

References (39)

1. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
2. Mazurek S., Boschek C.B., Hugo F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
3. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121:29-40.
4. Ganapathy V., Inoue K., Prasad P.D., Ganapathy M.E. Cellular uptake of amino acids: system and regulation. Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition 2004, 63-78. CRC Press, Boca Raton, FL. second ed. L.A. Cynober (Ed.).
5. Ganapathy V., Gupta N., Martindale R.G. Protein digestion and absorption. Physiology of the Gastrointestinal Tract 2006, 1667-1692. Raven Press, New York. fourth ed. L.R. Johnson (Ed.).
6. Bannai S., Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J. Membr. Biol. 1986, 89:1-8.
7. Patel S.A., Warren B.A., Rhoderick J.F., Bridges R.J. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of l-glutamate and l-cystine. Neuropharmacology 2004, 46:273-284.
8. Huang Y., Dai Z., Barbacioru C., Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005, 65:7446-7454.
9. Lo M., Ling V., Wang Y.Z., Gout P.W. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br. J. Cancer 2008, 99:464-472.
10. Ye Z.C., Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999, 59:4383-4391.
11. Savaskan N.E., Heckel A., Hahnen E., Engelhorn T., Doerfler A., Ganslandt O., Nimsky C., Buchfelder M., Eyupoglu I.Y. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 2008, 14:629-632.
12. Gout P.W., Buckley A.R., Simms C.R., Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia 2001, 15:1633-1640.
13. Iglehart J.K., York R.M., Modest A.P., Lazarus H., Livingston D.M. Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin. J. Biol. Chem. 1977, 252:7184-7191.
14. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27:922-935.
15. Narang V.S., Pauletti G.M., Gout P.W., Buckley D.J., Buckley A.R. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 2007, 53:210-217.
16. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
17. Qiao H.X., Hao C.J., Li Y., He X., Chen R.S., Cui J., Xu Z.H., Li W. JNK activation mediates the apoptosis of xCT-deficient cells. Biochem. Biophys. Res. Commun. 2008, 370:584-588.
18. Chen R.S., Song Y.M., Zhou Z.Y., Tong T., Li Y., Fu M., Guo X.L., Dong L.J., He X., Qiao H.X., Zhan Q.M., Li W. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009, 28:599-609.
19. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal. 2009, 11:777-790.
20. Scherz-Shouval R., Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci. 2010.
21. Christensen H.N. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol. Rev. 1990, 70:43-77.
22. Chillaron J., Roca R., Valencia A., Zorzano A., Palacin M. Heteromeric amino acid transporters: biochemistry, genetics, and physiology. Am. J. Physiol. Renal Physiol. 2001, 281:F995-F1018.
23. Verrey F., Closs E.I., Wagner C.A., Palacin M., Endou H., Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004, 447:532-542.
24. Bannai S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem. 1986, 261:2256-2263.
25. Eck H.P., Droge W. Influence of the extracellular glutamate concentration on the intracellular cyst(e)ine concentration in macrophages and on the capacity to release cysteine. Biol. Chem. Hoppe Seyler 1989, 370:109-113.
26. Rimaniol A.C., Mialocq P., Clayette P., Dormont D., Gras G. Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am. J. Physiol. Cell Physiol. 2001, 281:C1964-C1970.
27. Maechler P., Wollheim C.B. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 1999, 402:685-689.
28. Chung W.J., Lyons S.A., Nelson G.M., Hamza H., Gladson C.L., Gillespie G.Y., Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 2005, 25:7101-7110.
29. Bassi M.T., Gasol E., Manzoni M., Pineda M., Riboni M., Martin R., Zorzano A., Borsani G., Palacin M. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc. Pflugers Arch. 2001, 442:286-296.
30. Narang V.S., Pauletti G.M., Gout P.W., Buckley D.J., Buckley A.R. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 2003, 23:4571-4579.
31. Doxsee D.W., Gout P.W., Kurita T., Lo M., Buckley A.R., Wang Y., Xue H., Karp C.M., Cutz J.C., Cunha G.R., Wang Y.Z. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 2007, 67:162-171.
32. Reddy N.M., Kleeberger S.R., Bream J.H., Fallon P.G., Kensler T.W., Yamamoto M., Reddy S.P. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 2008, 27:5821-5832.
33. Seiler A., Schneider M., Forster H., Roth S., Wirth E.K., Culmsee C., Plesnila N., Kremmer E., Radmark O., Wurst W., Bornkamm G.W., Schweizer U., Conrad M. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008, 8:237-248.
34. Lastro M., Kourtidis A., Farley K., Conklin D.S. XCT expression reduces the early cell cycle requirement for calcium signaling. Cell. Signal. 2008, 20:390-399.
35. Hori K. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy 2005, 51:357-360.
36. Uren J.R., Lazarus H. l-cyst(e)ine requirements of malignant cells and progress toward depletion therapy. Cancer Treat. Rep. 1979, 63:1073-1079.
37. Gout P.W., Kang Y.J., Buckley D.J., Bruchovsky N., Buckley A.R. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 1997, 11:1329-1337.
38. Iwata S., Hori T., Sato N., Hirota K., Sasada T., Mitsui A., Hirakawa T., Yodoi J. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by l-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J. Immunol. 1997, 158:3108-3117.
39. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181.